United States securities and exchange commission logo

                           November 18, 2020

       Christian Schade
       Chairman and Chief Executive Officer
       Aprea Therapeutics, Inc.
       535 Boylston Street
       Boston, MA 02116

                                                        Re: Aprea Therapeutics,
Statement on Form S-3
                                                            Filed November 12,
                                                            File No. 333-250041

       Dear Mr. Schade:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason L.
Drory at 202-551-8342 with any questions.


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Istvan A. Hajdu, Esq.